Partnering

Scientific Collaboration

Building the Next Generation of
Immune Therapies Together

We actively partner with academic institutions, clinical research centers, hospitals, and biotech innovators to accelerate the discovery and development of first-in-class immunotherapies targeting metabolic checkpoints.

We’re particularly interested in
collaborations that help us

01 Advance our understanding of immune-metabolic regulation in cancer, metabolic, and immunological diseases.

02 Explore novel therapeutic targets in immuno-oncology and metabolic immunotherapy.

03 Discover ideal companion therapies for high-need indications to guide clinical development.

04 Accelerate the clinical translation of novel immune-modulating therapies.

If you interested in bringing innovative therapies to patients, we welcome the opportunity to collaborate.

Why Partner with Pilatus Biosciences?

Targeting the Root of Immune Suppression

We tackle the metabolic drivers of immune evasion. Our lead modality, PLT012, blocks CD36, a key regulator of lipid uptake in immune cells, reprogramming the tumor microenvironment (TME) to restore immune activity and enhance anti-tumor responses.

Dual Mechanisms to Address Hard-to-Treat Diseases

PLT012 has shown superior results in preclinical studies, achieving tumor remission in over 40% of cases when combined with standard therapies in hard-to-treat liver disease. PLT011, our second modality, combines PD-L1 blockade with T-cell rejuvenation to address resistant tumors and complement existing immunotherapies.

Pioneers in Immune Metabolism

We are advancing a new class of therapies focused on metabolic checkpoints, offering a novel solution where traditional immunotherapies fall short.

Recognized Innovation

PLT012 has received FDA Orphan Drug Designation for liver and intrahepatic bile duct cancers, validating its promise in addressing critical unmet needs.

Versatile for Combination Therapies

Designed to complement existing immunotherapies, our candidates offer broad potential in both monotherapy and combination settings—enhancing clinical outcomes and commercial value.

Partners

Scientific Collaboration

Building the Next Generation of
Immune Therapies Together

We’re particularly interested in
collaborations that help us

01

Advance our understanding of immune-metabolic regulation in cancer, metabolic, and immunological diseases.

02

Explore novel therapeutic targets in immuno-oncology and metabolic immunotherapy.

03

Discover ideal companion therapies for high-need indications to guide clinical development.

04

Accelerate the clinical translation of novel immune-modulating therapies.

Why Partner with Pilatus Biosciences?

Targeting the Root of Immune Suppression

We tackle the metabolic drivers of immune evasion. Our lead modality, PLT012, blocks CD36, a key regulator of lipid uptake in immune cells, reprogramming the tumor microenvironment (TME) to restore immune activity and enhance anti-tumor responses.

Dual Mechanisms to Address Hard-to-Treat Diseases

Pioneers in Immune Metabolism

We are advancing a new class of therapies focused on metabolic checkpoints, offering a novel solution where traditional immunotherapies fall short.

Recognized Innovation

PLT012 has received FDA Orphan Drug Designation for liver and intrahepatic bile duct cancers, validating its promise in addressing critical unmet needs.

Versatile for Combination Therapies

Designed to complement existing immunotherapies, our candidates offer broad potential in both monotherapy and combination settings—enhancing clinical outcomes and commercial value.

Partners

Unlocking Immune Potential with
Innovative Metabolic Reprogramming

Pilatus Biosciences

Links

Scientific Collaboration

Building the Next Generation ofImmune Therapies Together

We’re particularly interested incollaborations that help us

01

Advance our understanding of immune-metabolic regulation in cancer, metabolic, and immunological diseases.

02

Explore novel therapeutic targets in immuno-oncology and metabolic immunotherapy.

03

Discover ideal companion therapies for high-need indications to guide clinical development.

04

Accelerate the clinical translation of novel immune-modulating therapies.

Why Partner with Pilatus Biosciences?

Targeting the Root of Immune Suppression

We tackle the metabolic drivers of immune evasion. Our lead modality, PLT012, blocks CD36, a key regulator of lipid uptake in immune cells, reprogramming the tumor microenvironment (TME) to restore immune activity and enhance anti-tumor responses.

Dual Mechanisms to Address Hard-to-Treat Diseases

Pioneers in Immune Metabolism

We are advancing a new class of therapies focused on metabolic checkpoints, offering a novel solution where traditional immunotherapies fall short.

Recognized Innovation

PLT012 has received FDA Orphan Drug Designation for liver and intrahepatic bile duct cancers, validating its promise in addressing critical unmet needs.

Versatile for Combination Therapies

Designed to complement existing immunotherapies, our candidates offer broad potential in both monotherapy and combination settings—enhancing clinical outcomes and commercial value.

Partners

Unlocking Immune Potential withInnovative Metabolic Reprogramming

Pilatus Biosciences

Links

Building the Next Generation of
Immune Therapies Together

We’re particularly interested in
collaborations that help us

Unlocking Immune Potential with
Innovative Metabolic Reprogramming